Unlock stock picks and a broker-level newsfeed that powers Wall Street. Upgrade Now Mexico - Delayed Quote • MXN uniQure N.V. (QUREN.MX) Follow Compare 325.95 +1.46 +(0.45%) At close: December 11 at 10:12:13 AM CST Comparisons Indicators Technicals Corporate Events Draw List View Grid View Detach Attach No Tool Measure UNDO Redo All All Favorites Text Statistics Technicals Fibonacci Markings Lines Annotation Arrow Line Horizontal Vertical Rectangle Trend Line Measurement Line Average Line Callout Channel Check Continuous Crossline Elliott Wave Ellipse Doodle Fib Projection Fib Arc Fib Fan Fib Time Zone Focus Gann Fan Gartley Heart Pitchfork Quadrant Lines Ray Regression Line Fib Retracement Star Speed Resistance Arc Speed Resistance Line Time Cycle Tirone Levels Volume Profile Cross Magnet Clear All Drawings Restore Default Parameters Loading Chart for QUREN.MX 1D 5D 1M 3M 6M YTD 1Y 5Y All Date Range 1 min Recent News: QUREN.MX View More All News Press Releases SEC Filings uniQure Full Year 2024 Earnings: Misses Expectations uniQure Announces 2024 Financial Results and Highlights Recent Company Progress uniQure N.V. (NASDAQ:QURE) is a favorite amongst institutional investors who own 66% CSL Behring's Gene Therapy HEMGENIX® (etranacogene dezaparvovec-drlb) Four Years Post-Infusion Data Continue to Show Sustained Efficacy and Safety in Adults with Hemophilia B uniQure Announces Completion of Enrollment in the First Cohort and Favorable Recommendation from the Independent Data Monitoring Committee for its Phase I/IIa Clinical Trial of AMT-191 for the Treatment of Fabry Disease uniQure Announces Favorable Recommendation from Independent Data Monitoring Committee for its Phase I/II EPISOD1 Clinical Trial of AMT-162 for the Treatment of SOD1-ALS uniQure Announces Pricing of its Public Offering uniQure Announces Proposed Public Offering uniQure price target raised to $32 from $12 at Stifel Up 152% in December, Is uniQure a Good Stock to Buy Now and Hold Through 2025? UniQure Stock Doubles After Striking A Deal With The FDA For Huntington's Drug